How Fast Can a US Sponsor of Record Be in Place for an FDA IDE Study?

The Regulatory Starting Point: 21 CFR 812.18(a)

Under 21 CFR 812.18(a), a company outside the United States cannot itself sponsor an FDA Investigational Device Exemption (IDE) study. A US person, meaning an individual or legal entity with a US address and legal standing, must act as the sponsor of record. This is not a procedural formality. It is a hard regulatory requirement that determines who signs the IDE application, who assumes legal accountability to FDA, and who receives all agency correspondence throughout the life of the study. For any non US device developer seeking to enter a US clinical trial, the first operational question is not 'which IRB do we use?' or 'how do we write the protocol?' The first question is: who is our US Sponsor of Record, and how quickly can that structure be in place?

Contracted Sponsor of Record vs. US Subsidiary: A Direct Comparison

A contracted US Sponsor of Record through a qualified regulatory consulting firm can typically be operational within days of a signed engagement agreement, because the legal entity, regulatory infrastructure, and FDA-facing personnel already exist. By contrast, forming and staffing a US subsidiary generally takes months, accounting for state incorporation timelines, registered agent setup, EIN acquisition, banking, and hiring qualified regulatory personnel who understand IDE obligations under 21 CFR Part 812.

For device developers under competitive or clinical timeline pressure, that difference is not trivial. Months of delay at the sponsor establishment stage can push first-patient-in dates back by an entire study cycle.

What Must Be Ready Before Speed Matters

Even with a contracted US Sponsor of Record that can move within days, the sponsor cannot file or manage an IDE study without foundational inputs from the device developer. Speed at the sponsor level is only useful when the following elements are prepared or in active development.

• Device Description: A clear, technically accurate description of the investigational device, including its intended use, technological characteristics, and any predicate or comparable device context. This is the foundation for every regulatory assessment that follows, including the IDE application under 21 CFR 812.20.
• Study Risk Determination (Significant Risk or Nonsignificant Risk): FDA requires that every IDE study be categorized as either a significant risk (SR) or nonsignificant risk (NSR) device study before the appropriate regulatory pathway is selected. SR studies require full IDE approval from FDA before any study may begin. NSR studies may proceed under an abbreviated IDE, subject to IRB approval alone, under 21 CFR 812.2(b). This determination is not automatic. It requires a structured review of the device, the proposed study design, and applicable FDA guidance, including the FDA guidance document 'Significant Risk and Nonsignificant Risk Medical Device Studies' (issued January 2006 and still the controlling reference). ADB can review available device and study information to support this risk classification assessment, but the sponsor must come to the table with enough device and study context to make that review meaningful.
• Protocol Development Stage: The sponsor of record is legally responsible for the study protocol under 21 CFR 812.25. Knowing whether a protocol is fully drafted, in outline form, or still conceptual directly affects the timeline to IDE submission. A contracted sponsor can work alongside the developer to review and prepare the protocol, but a blank page at engagement adds weeks, not days, to the critical path.

What the US Sponsor of Record Is Responsible For

It is worth being precise about scope, because the role is broader than many non US developers initially assume. Under 21 CFR Part 812, the sponsor of record is responsible for submitting the IDE application, maintaining sponsor records, monitoring the investigation, selecting qualified investigators, ensuring investigator agreements are in place under 21 CFR 812.43, submitting progress reports and adverse device effect reports to FDA, and maintaining the IDE in good standing throughout the study. These are not tasks that can be informally shared with the non US developer without a documented, structured arrangement. The sponsor holds the obligation in FDA's eyes.

ADB's Position in This Space

ADB Consulting and CRO Inc. serves as a contracted US Sponsor of Record for non US medical device developers conducting FDA-regulated IDE studies in the United States, providing the regulatory infrastructure, FDA-facing accountability, and study oversight required under 21 CFR Part 812 so that developers without a US legal presence can pursue US clinical evidence on an accelerated and compliant timeline. Learn more at adbccro.com/us-sponsor.

Reviewed October 24, 2026 by ADB's regulatory team.

Frequently Asked Questions

How fast can a US Sponsor of Record be put in place?

When a device developer has a signed engagement agreement with ADB and has the foundational inputs ready, including a device description, a preliminary risk determination, and a protocol in active development, a contracted US Sponsor of Record through ADB can be operational within days. This contrasts with the months typically required to form, register, and staff a new US subsidiary entity.

How fast can a US Sponsor of Record be put in place if our protocol is not yet finalized?

The sponsor of record structure itself can still be established quickly. However, the timeline to IDE submission will be governed by how long it takes to prepare a complete protocol that meets the requirements of 21 CFR 812.25. ADB's team can review your draft protocol and prepare it toward submission readiness, but developers should plan for additional lead time when protocol development is early stage.

How fast can a US Sponsor of Record be put in place if we have not yet determined whether our study is significant risk or nonsignificant risk?

The risk classification review can be conducted as part of the early engagement process. ADB's regulatory team will assess available device and study information against FDA's January 2006 guidance on significant risk and nonsignificant risk device studies and the criteria in 21 CFR 812.3(m). This assessment informs which regulatory pathway applies and, by extension, how quickly the study may begin enrolling. Completing this determination early is one of the highest-leverage steps a developer can take to protect its overall clinical timeline.

Ready to Assess Your Path to a US Sponsor of Record?

If you are a non US medical device developer preparing for a US clinical study, or a US-based startup that needs an experienced sponsor infrastructure without building it internally, ADB Consulting and CRO Inc. is ready to review your situation and help you understand your options. Book a free discovery call with Andre Butler and the ADB regulatory team at adbccro.com/us-sponsor. There is no obligation and no generic pitch. You will leave with a clearer picture of what your US sponsor pathway looks like and how quickly you can move.

If this applies to your program, our US Sponsor of Record program walks through the process in detail.